Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

NCT03213665 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03213665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2017
Completion date
December 31, 2024
Enrollment
20 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, ann arbor stage iii hodgkin lymphoma, ann arbor stage iii non-hodgkin lymphoma, ann arbor stage iv hodgkin lymphoma, ann arbor stage iv non-hodgkin lymphoma, ewing sarcoma/peripheral primitive neuroectodermal tumor, low grade glioma, recurrent ependymoma, recurrent ewing sarcoma, recurrent glioma, recurrent hepatoblastoma, recurrent hodgkin lymphoma, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent primary central nervous system neoplasm, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, refractory hodgkin lymphoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory soft tissue sarcoma, rhabdoid tumor, stage iii soft tissue sarcoma ajcc v7, stage iv soft tissue sarcoma ajcc v7, wilms tumor